• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
IMCS

IMCS

A leader in recombinant enzymes and automated micro-chromatography technologies

  • ABOUT
    • ABOUT IMCS
    • QUALITY POLICY
    • RESEARCH AT IMCS
    • CAREERS
  • PRODUCTS
    • IMCSzyme®
      • IMCSzyme E1F
      • IMCSzyme RT
      • IMCSzyme® CATALOG
    • IMCStips®
      • APPLICATIONS
        • AFFINITY
        • SIZE EXCLUSION
        • NUCLEIC ACIDS
        • ION EXCHANGE
        • REVERSE PHASE
        • PHOSPHOPEPTIDE
      • IMCStips® CATALOG
      • AUTOMATION PLATFORMS
        • DYNAMIC DEVICES
        • HAMILTON
        • INTEGRA
        • TECAN
        • OPENTRONS
        • ANALYTIK JENA
    • SULFATASES
      • Sulfazyme
      • Sulfazyme™ DS
      • Sulfazyme™ β-AS
    • GLYCO REAGENTS
      • GLYCOLIPIDS
      • ACTIVATED SUGARS
      • BIOSYNTHETIC ENZYMES
      • SMALL MOLECULES
    • SPHINGOSINES
    • OTHER PROTEINS
      • PURIFIED STREPTAVIDIN
      • B. pi. β-glucuronidase variant
  • SERVICES
    • BETA-GLUCURONIDASES & SULFATASES
      • β-GLUCURONIDASE VALIDATION SERVICES
      • HIGH-THROUGHPUT TOXICOLOGY WORKFLOWS
    • IMCStips®
      • SAMPLE PREPARATION AUTOMATION
      • HIGH-THROUGHPUT METHOD DEVELOPMENT
      • AUTOMATION PLATFORMS
        • DYNAMIC DEVICES
        • HAMILTON
        • INTEGRA
        • TECAN
        • OPENTRONS
        • ANALYTIK JENA
    • OTHER SERVICES
      • GLYCAN PRODUCTION (Coming Soon)
      • R&D COLLABORATIONS
      • EXTRACELLULAR VESICLES
  • RESOURCES
    • FAQ
    • IMCSZYME RESOURCES
    • IMCSTIPS RESOURCES
    • SAFETY DATA SHEETS
    • CERTIFICATE OF ANALYSIS
  • LATEST NEWS
    • LATEST NEWS
    • PODCAST
    • BLOG
    • EVENTS
    • WEBINARS
  • SHOP
  • CONTACT
  • en
    • en
    • es
    • fr
    • de
    • zh-CN
Image of blue rendered molecular structure

Case Study: Harmonizing Automated Protein A Purification Workflows Across Multiple Sites

Automated IgG Purification using IMCStips® and Hamilton Microlab® STAR™

Presenters and Moderator

sderi_pic-244x300

Stephen D'Eri, MS

Associate Director at Sanofi
1517236061784

Janna Liptak, MS

Scientist, Automation Specialist at Sanofi
2022-10-08T23_16_20

Carter Mitchell, PhD

Chief Science Officer at Kemp Proteins

Executive Summary

This case study describes how Sanofi harmonized its automated Protein A purification workflows across multiple sites using Protein A IMCStips® (ProA IMCStips) and SizeX IMCStips on the Hamilton Microlab STAR. ProA IMCStips enable simultaneous purification of harvest samples in a 96-well plate, and consistently high recovery and quality of protein A eluates have been demonstrated. SizeX IMCStips enable simultaneous desalting of a full 96-well plate for denatured, reduced, and alkylated samples prior to tryptic digestion. The inter- and intra-plate reproducibility are comparable to manual approaches. This automated method can detect trending modifications without bias and has passed qualification showing suitable accuracy, precision, linearity, and repeatability for known modifications quantified via targeted LC-MS analysis.

Challenges

Although Sanofi operates this method across several sites globally, there were many challenges such as redundancy in analytics as well as labor-intensive and variable sample preparations. In the early stages of developing and optimizing the automated tryptic digest method, laboratory results show artificially high and inconsistent levels of asparagine deamination due to cysteine reduction conditions associated with the method. Using the PENNY peptide serving as a global indicator of deamination, absolute levels of deamination were observed to be very high. Automated method yielded levels 9-11% deamination compared to 2-5% deamination from a manual run and varying levels of deamination were shown across different sites. Additionally, some man methods require long run times to achieve chromatographic separation of analytes of interest and visual inspection of data strongly suggests peptide degradation and increase in oxidation as a function of autosampler dwell time. Sanofi hoped to develop a fully automated, harmonious workflow for protein A purification, A280 analysis, and tryptic digest across multiple sites.

How IMCS Helped

Overall, IMCS helped Sanofi to transition from a semi-automated to a fully automated workflow. The IMCStips were the enabling technology for automated protein A purification workflow that allowed for low variability, high reproducibility, and high recovery. And the SizeX IMCStips were used during the buffer exchange step and allowed Sanofi to transition from a low throughput manual tube-base digest to a high throughput automated plate-based digest. Implementing this fully automated workflow allowed Sanofi to also save a lot of time, requiring the analyst to only be there at the beginning to set up the deck and at the end to grab their sample.

Results

PROTEIN A RESULTS Expand

Purification Yield

  • Tested a full 96-well plate containing mostly harvest with some drug substance samples
  • No major difference in percent recovery between drug substance and harvest
  • Approximately 85% overall recovery

LC/MS Analysis

  • Inherent minor differences between drugs and harvest
  • Post-translation modifications: overall modifications were low and RSD <10% (low variability across the plate)
  • Glycopeptides: RSD <15% (good reproducibility across the plate)

Size Exclusion Chromatography (SEC) Results

  • Low variability
TRYPTIC DIGEST RESULTS Expand

Reproducibility

  • Design: 96-well plate with monoclonal antibodies and digested with automated method vs. 12 manual digest with same sample -> LC/MS instrument; performed 3x across 3 separate days to look at intra- and inter-plate reproducibility
  • Visually similar; no major differences in peptide intensity; profiles consistent
  • Log2 ratio of peptide areas mostly between -1 and 1 -> showed comparable results between automated and manual
  • Intra-plate variability (% RSD across 96 samples within each plate): mainly <20%
  • Inter-plate variability mostly <20%

Trending Modifications

  • Design: 1) forced deamination mAb1 incubated at 45° for 0, 1, 2, and 4 weeks; 2) forced glycation mAb2 incubated with glucose for 0, 1, 4, and 6 days; 3) forced oxidation tsAb1 incubated with H2O2 for 0, 1, 4, and 6 hours -> each sample randomized on 96-well plate (modification level is independent of plate position)
  • Able to detect trending modifications without bias using automated digest; modification levels increase with stress; RSD mostly <5%

Qualification

  • Design: stressed sample -> combined with drug substance -> 6 different spike levels (followed 2 oxidation and 2 deamination sites) -> automated digest -> LC/MS
  • Intermediate precision: RSD <20% for each modification site for each spike level
  • Accuracy: ratio of observed to expected percent modification between 70-130%
  • Linearity: R2 ≥ 0.98
  • Repeatability: RSD <20% within digest occasions

Quotes from Presentation

"This automated workflow takes about an hour to set up the deck [and] that’s really the only hands-on time for the analyst. If you think about just the digestion when we were doing it manually, an analyst could probably do around 24 samples a day, and [often] would take them a full 8 hours: 3 hours of hands-on time, but they would have to be there the whole time. And that’s just for 24 samples. If you wanted to do 96, you are talking about 3 to 4 days. So, implementing these IMCStips helped to fully automate that workflow, and make sure that the user only had to be there at the beginning to set up the deck and at the end to grab their sample. They might not even have to be there to retrieve their sample at the end. They might just have their data output to them."

"We don’t really know of other tips that are like the SizeX tips to do that buffer exchange step. So, that’s really where IMCS stood out for us. Showing all this data of IMCS, we were happy with the results we got. The workflow that we had was really working out for us."

"In developing and optimizing the Protein A tips in house, we consistently monitor where all the samples have gone to in different wash and elution steps. By process of elimination, we saw that the IMCS Protein A consistently captured, if I had to put a number on it, greater than 92%. We can always account for close to 100% of our sample, whether it ended up in the wash based on our buffers, in the elution, or whether it remained on the tip when we were optimizing the elution procedure. Indirectly, we measured that they captured a very high harvest."

"IMCS provided the basic scripts; these were sub-methods that we could just plug right into our entire Hamilton method. From there, we could plug in different inputs so we could change the number of aspirate and dispense cycles or the volume that we’re aspirating and dispensing each time. It has flexibility that we could change any of those inputs. The base method was already there. There were also firmware controls. The tips are cut at the bottom, so you need to make sure the Hamilton method knows that it’s using these different types of tips. It made it easy and flexible for us to continue to optimize based on what’s needed for our group."

Related Content

Sanofi webinar thumb
AUTOMATING PROTEIN A PURIFICATION THROUGH TRYPTIC DIGEST LC-MS/MS ...

Join Stephen D’Eri, Automation Lead, Bioanalytics and Janna Liptak, Senior Research Associate, Automation, Bioanalytics from Sanofi...

WATCH NOW
title_slide
LEVERAGING AUTOMATED HIGH-THROUGHPUT CLONAL SELECTION...

Join our experts as they walk you through the tools and techniques to help contract research organizations and pharma R&D...

WATCH NOW

Ready to get started? Contact us today for a free sample!

Get Started

Sidebar

"*" indicates required fields

Name*
Email me a copy
Consent

Customize Your Workflow

IMCS recognizes our customers’ needs vary, which is why we provide tailored tools and services to help you reach your laboratory’s goals.

VIEW OUR CUSTOM SOLUTIONS

ABOUT IMCS

INTEGRATED MICRO-CHROMATOGRAPHY SYSTEMS, INC. (IMCS) IS A BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING TOOLS AND SERVICES THAT HELP PAVE THE WAY FOR THE FUTURE OF PRECISION MEDICINE. WE STRIVE TO ADDRESS THE GROWING NEEDS OF CLINICAL AND RESEARCH LABORATORIES THROUGH ADVANCED TECHNOLOGIES THAT INCREASE TESTING EFFICIENCY AND ACCURACY.

STAY UP TO DATE

WANT REGULAR UPDATES ON OUR INNOVATIVE PRODUCTS?
Sign up to receive exclusive emails and offers from IMCS.
!
!
!
Subscribe
Something went wrong. Please check your entries and try again.

ABOUT

ABOUT IMCS

CAREERS

QUALITY POLICY

RESEARCH AT IMCS

PRODUCTS

IMCSZYME

IMCSZYME RT

IMCSTIPS

PROTEINS, ENZYMES, RESINS

GLYCO REAGENTS

TERMS

TERMS OF USE

PRIVACY POLICY

STANDARD TERMS AND CONDITIONS

FCOI POLICY

CONNECT WITH US

IMCS, Inc. Headquarters
110 Centrum Drive
Irmo, SC 29063

  • IMCS LinkedIn Page
  • IMCS Facebook Page
  • IMCS Twitter Page

COPYRIGHT © 2026 · IMCS · ALL RIGHTS RESERVED ·

Return to top

Get Started Today!

Please fill out the form below to get started.

"*" indicates required fields

Step 1 of 3

33%
Which IMCStips applications you are interested in? Please select all that apply.*
Name*
Automated Liquid Handling System*
Consent*

Caleb-Schlachter-for-web

Caleb R. Schlachter, Ph.D.

Principal Scientist
Caleb R. Schlachter, Ph.D., as the Principal Scientist at IMCS, leads and provides guidance for several research and development projects that involve proteins, including enzymes for glycan hydrolysis and glycan synthesis. He has co-authored multiple patents, posters, and peer-reviewed articles on β-glucuronidases and sulfatases.
Gray Amick for web

Gray D. Amick, Ph.D.

Director of Operations
Gray D. Amick, Ph.D., is the Director of Operations at IMCS with over 26 years of experience in forensic DNA analysis and toxicology. Prior to joining IMCS, he led forensic DNA testing for the Richland County Sheriff’s Department as technical leader and lab director. He has been court-qualified as an expert over 100 times and has authored and co-authored multiple posters and peer-reviewed articles.
Amanda M Headshot

Amanda C. McGee

Research Scientist
Amanda C. McGee is a Research Scientist at IMCS involved with enzyme characterizations, new analytical method developments, and advanced technical support. She joined IMCS with several years of experience in analytical testing for active pharmaceutical ingredients as per cGMP, USP and ICH guidelines. She has co-authored peer reviewed articles in the Journal of Analytical Toxicology and presented research at national and international conferences.
Andrew_Headshot

L. Andrew Lee, Ph.D.

Co-Founder and Chief Scientific Officer
L. Andrew Lee, Ph.D. co-founded IMCS and leads research and development efforts in enzyme engineering and automated micro-chromatography workflows. He directs new market efforts in glycan synthesis, supported by three NIH Fast-Track awards.

Get started with 2N1 below

"*" indicates required fields

Name*
Would you be interested in joining the 2N1 beta program?*
Which product are you interested in? (select all that apply)*
What are your current purification workflows? (select all that apply)*
Please select your automation platform(s) (select all that apply)*
How soon are you planning on evaluating 2N1?*
Consent*

DOWNLOAD OUR POSTERS

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Please select the posters you would like to download*
Name*
Please provide a valid email so we can send you the download link.
Location*
Automated Liquid Handling System
Contact preferences*
Consent*

Podcast Form

"*" indicates required fields

Name*
How would you like to connect?*
Please let us know what's on your mind. Have a question for us? Ask away.

Ready for a change? Get your FREE sample of IMCSzyme® RT today.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
Consent*